JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roux, S.
Right arrow Articles by Clozel, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roux, S.
Right arrow Articles by Clozel, M.

Vol. 283, Issue 3, 1110-1118, 1997

Ro 61-1790, a New Hydrosoluble Endothelin Antagonist: General Pharmacology and Effects on Experimental Cerebral Vasospasm

Sébastien Roux, Volker Breu, Thomas Giller, Werner Neidhart, Henri Ramuz, Philippe Coassolo, Jean Paul Clozel and Martine Clozel

F. Hoffmann-La Roche Ltd., Basel, Switzerland

Endothelin (ET) receptor antagonists are of great potential clinical interest for the treatment pathological conditions associated with vasospasm, such as subarachnoid hemorrhage (SAH). We developed for parenteral use a compound of a class of trifunctionalized heteroarylsulfonamide pyrimidines specially designed for high water solubility. Ro 61-1790 [5-methyl-pyridine-2-sulfonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide] is a competitive ET antagonist with an affinity to ETA receptor in the subnanomolar range. It has a ~1000-fold selectivity for the ETA vs. the ETB receptor as assessed on functional assays (e.g., ET-1-induced inositol-1,4,5-triphosphate release or ET-1-induced intracellular calcium mobilization). Ro 61-1790 also had a high functional potency for inhibiting contraction induced by ET-1 on isolated rat aorta (ETA receptors; pA2 = 9.5) or by sarafotoxin S6c on rat trachea (ETB receptors; pA2 = 6.4). In vivo, Ro 61-1790 inhibited the pressor effect of big ET-1 in pithed rats with an ID50 value of 0.05 mg/kg. Intravenous bolus of Ro 61-1790 induced a long-lasting antihypertensive effect in deoxycorticosterone acetate salt rats instrumented with telemetry. In a double-hemorrhage canine model of SAH, Ro 61-1790 both prevented and reversed cerebral vasospasm in a dose-dependent manner. In an established cerebral vasospasm, 3 mg/kg Ro 61-1790 i.v. was half as efficacious as intrabasilar papaverine. Ro 61-1790 (20 mg/kg/day) totally prevented the occurrence of vasospasm. In summary, these data demonstrate that Ro 61-1790 is a potent and selective ETA receptor antagonist suitable for parenteral use and potentially useful for preventing delayed ischemic deficit in patients with SAH.

0022-3565/97/2833-1110$03.00/0
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 StrokeHome page
R. L. Macdonald, N. F. Kassell, S. Mayer, D. Ruefenacht, P. Schmiedek, S. Weidauer, A. Frey, S. Roux, A. Pasqualin, and on behalf of the CONSCIOUS-1 Investigators
Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1): Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial
Stroke, November 1, 2008; 39(11): 3015 - 3021.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
P. L. M. van Giersbergen, K. A. Gunawardena, and J. Dingemanse
Influence of Ethnic Origin and Sex on the Pharmacokinetics of Clazosentan
J. Clin. Pharmacol., November 1, 2007; 47(11): 1374 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug.
Experimental Biology and Medicine, June 1, 2006; 231(6): 653 - 695.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. Konczalla, H. Vatter, S. Weidauer, A. Raabe, and V. Seifert
Alteration of the cerebrovascular function of endothelin B receptor after subarachnoidal hemorrhage in the rat.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1064 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Okajima, R. Parent, E. Thorin, and M. Lavallee
Pathophysiological plasma ET-1 levels antagonize {beta}-adrenergic dilation of coronary resistance vessels in conscious dogs
Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1476 - H1483.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Parent and M. Lavallee
Endothelin-dependent effects limit flow-induced dilation of conductance coronary vessels after blockade of nitric oxide formation in conscious dogs
Cardiovasc Res, January 14, 2000; 45(2): 470 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. D. Tune, K. N. Richmond, M. W. Gorman, R. A. Olsson, and E. O. Feigl
Adenosine is not responsible for local metabolic control of coronary blood flow in dogs during exercise
Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H74 - H84.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. Thorin, R. Parent, Z. Ming, and M. Lavallee
Contribution of endogenous endothelin to large epicardial coronary artery tone in dogs and humans
Am J Physiol Heart Circ Physiol, August 1, 1999; 277(2): H524 - H532.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
C Guibert and D J Beech
Positive and negative coupling of the endothelin ETA receptor to Ca2+-permeable channels in rabbit cerebral cortex arterioles
J. Physiol., February 1, 1999; 514(3): 843 - 856.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
Z. Ming, R. Parent, E. Thorin, and M. Lavallee
Endothelin-Dependent Tone Limits Acetylcholine-Induced Dilation of Resistance Coronary Vessels After Blockade of NO Formation in Conscious Dogs
Hypertension, November 1, 1998; 32(5): 844 - 848.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. Zuccarello, R. Boccaletti, A. Romano, R. M. Rapoport, and J. P. Muizelaar
Endothelin B Receptor Antagonists Attenuate Subarachnoid Hemorrhage–Induced Cerebral Vasospasm • Editorial Comment
Stroke, September 1, 1998; 29(9): 1924 - 1929.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.